Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice

Journal of Medicinal Chemistry

Volumn 47, Issue 27, 2004, Pages 6716-6729

  Patel, Jyoti B ^a   Huynh, Carlic K ^a   Handratta, Venkatesh D ^a   Gediya, Lalji K ^a   Brodie, Angela M H ^a   Goloubeva, Olga G ^b   Clement, Omoshile O ^c   Nanne, Ivo P ^d   Soprano, Dianne Robert ^e   Njar, Vincent C O ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c ACCELRYS INC   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^e TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(1H IMIDAZOL 1 YL)RETINOIC ACID; 2 [4 [2 [8 CYCLOPROPYL 4,4 DIMETHYLSPIRO(CHROMANE 2,1' CYCLOPROPANE) 6 YL]ETHYNYL] 2 FLUOROPHENYL]ACETIC ACID; 4 (1H IMIDAZOL 1 YL) N (IMIDAZOLYL)RETINAMIDE; ANTINEOPLASTIC AGENT; ISOTRETINOIN; LIAROZOLE FUMARATE; METHYL 9 (3 IMIDAZOLYL 2,6,6 TRIMETHYLCYCLOHEX 1 ENYL) 3,7 DIMETHYLNONA 2,4,6,8 TETRAENOATE; N [4 [2 (DIMETHYLAMINO) 1 (1H IMIDAZOL 1 YL)PROPYL]PHENYL] 2 BENZOTHIAZOLAMINE; R 116010; RECEPTOR BLOCKING AGENT; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR BLOCKING AGENT; RETINOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG TOLERABILITY; ENANTIOMER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; RECEPTOR BINDING; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CRICETINAE; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; MICROSOMES, LIVER; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; STEREOISOMERISM; TRANSPLANTATION, HETEROLOGOUS; TRETINOIN;

EID: 19944428412     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0401457     Document Type: Article

References (58)

1. Mangelsdorf, D. A.; Umesono, K.; Evans, R. M. In The Retinoids; Sporn, M. B., Roberts, A. B., Goodman, D. S., Eds.; Raven Press: New York, 1994; pp 319-349.
2. Mundi, J.; Frankel, S. R.; Miller, W. H., Jr.; Jakubowski, A.; Scheinberg, D. A.; Young, C. W.; Dmitrovski, E.; Warrell, R. P., Jr. Continuous treatment with all-trans-retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid 'resistance' in patients with acute promyelocytic leukemia. Blood 1992, 79, 299-303.
3. Mundi, J.; Scher, H. I.; Rigas, J. R.; Warrell, R. P., Jr.; Young, C. W. Elevated plasma lipid peroxide content correlates with rapid plasma clearance of all-trans-retinoic acid in patients with advanced cancer. Cancer Res. 1994, 54, 2125-2128.
4. Lee, J. S.; Newman, R. A.; Lippman, S. M.; Huber, M. H.; Minor, T.; Raber, M. N.; Krakoff, I. H.; Hong, W. K. Phase 1 evaluation of all-trans-retinqic acid in adults with solid tumors. J. Clin. Oncol. 1893, 11, 959-966.
5. Miller, W. H., Jr. The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer 1998, 83, 1471-1482.
6. Njar, V. C. O. Cytochrome P450 retinoic acid 4-hydroxylase inhibitors: Potential agents for cancer therapy. Mini-Rev. Med. Chem. 2002, 2, 261-269.
7. Freyne, E.; Raeymaekers, A.; Venet, M.; Sanz, G.; Wouters, W.; De Coster, R.; Van Wauwe, J. Synthesis of Liazal™, a retinoic acid metabolism blocking agent (RAMBA) with potential clinical applications in oncology and dermatology. Bioorg. Med. Chem. Lett. 1998, 8, 267-272.
8. Thacher, S. M.; Vasudenvan, J.; Tsang, K.-Y.; Nagpal, S.; Chandraratna, R. A. S. New dermatological agents for the treatment of psoriasis. J. Med. Chem. 2001, 44, 287-296.
9. Frolik, C. A.; Roberts, A. B.; Tavala, T. E.; Roller, P.; Newton, D. L.; Sporn, M. B. Biochemistry 1979, 18, 2092-2097.
10. Nadin, L., Murray, M. Participation of CYP2C8 in retinoic acid 4-hydroxylation in hepatic microsomes. Biochem. Pharmacol. 1899, 58, 1201-1208.
11. McSorley. L. C.; Daly, A. K. Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. Biochem. Pharmacol. 2000, 60, 517-526.
12. Marill, J.; Cresteil, T.; Lanotte, M.; Chabot, G. G. Identification of human cytochrome P450 involved in the formation of all-trans-retinoic acid principal products. Mol. Pharmacol. 2000, 58, 1341-1348.
13. White, J. A.; Guo, Y.-D.; Baetz, K.; Beckett-Jones, B.; Bonasoro, J.; Hsu, K. E.; Dilworth, F.; Jones, G.; Petkovich, M. Identification of the retinoic acid-inducible all-trans-retinoic acid 4-hydroxylase. J. Biol. Chem. 1996, 271, 29922-29927.
14. White, J. A.; Beckett-Jones, B.; Guo, Y.-D.; Dilworth, F. J.; Bonasoro, J.; Jones, G.; Petkovich, M. cDNA cloning of human retinoic acid metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450 (CYP26). J. Biol. Chem. 1997, 272, 18538-18541.
15. Ray, W. J.; Bain, G.; Yao, M.; Gottlieb, D. I. CYP26, a novel mammalian cytochrome P450 is induced by retinoic acid and defines a new family. J. Biol. Chem. 1997, 272, 18702-18708.
16. Abu-Abed, S. S.; Beckett, B. R.; Chiba, H.; Chithalen, J. V.; Glenville, J.; Metzger, D.; Chambon, P.; Petkovich, M. Mouse P450RAI (CYP26) expression and retinoic acid-inducible retinoic acid metabolism in F9 cells are regulated by retinoic acid receptor γ and retinoid X receptor α. J. Biol. Chem. 1998, 273, 2409-2415.
17. Sonneveld, E.; Van der Sagg, P. T. Metabolism of retinoic acid: implications for development and cancer. Int. J. Vitam. Nutr. Res. 1998, 68, 404-410.
18. Marill, J.; Idres, N.; Capron, C. C.; Nguyen, E.; Chabot, G. G. Retinoic acid metabolism and mechanism of action: A review. Curr. Drug Metab. 2003, 4, 1-10.
19. Bhat, P. V.; Lacroix, A. Metabolism of retinal and retinoic acid in N-methyl-N-nitrosourea-induced mammary carcinomas in rats. Cancer Res. 1989, 49, 139-144.
20. Wouters, W.; Van Dun, J.; Dillen, A.; Coene, M.-C.; Cools, W.; De Coster, R. Effects of liarozole, a new antitumoral compound on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 breast cancer cells. Cancer Res. 1992, 52, 2841-2846.
21. Krekels, M. D. W. G.; Zimmerman, J.; Janssen, B.; Van Ginckel, R.; Van Hove, C.; Coene, M.-C.; Wouter, W. Analysis of the oxidative catabolism of retinoic acid in rat Dunning R 3327G prostate tumors. Prostate 1996, 29, 36-41.
22. Han, I. S.; Choi, J.-H. Highly specific cytochrome P450-like enzynes for all-trans-retinoic acid in T47D human breast cancer cells. J. Clin. Endocrinol. Metab. 1996, 81, 2069-2075.
23. Krekels, M. D. W. G.; Verhoeven, A.; van Dun, J.; Cools, W.; Van Hove, C.; Dillen, L.; Coene, M.-C.; Wouters, W. Induction of oxidative catabolism of retinoic acid in MCF-7 cells. Br. J. Cancer 1997, 75, 1098-1104.
24. Van der Leede, J., Van der Brink, C. E., Pijnappel, W. M.; Sonneveld, E.; Van der Saag, P. T.; Van der Burg, B. Autoinduction of retinoic acid metabolism to polar derivatives with decreased biological activity in retinoic acid-sensitive, but not in retinoic acid-resistant breast cancer cells. J. Biol. Chem. 1997, 272, 17921-17928.
25. Sonneveld, E.; Van der Brink, C. E.; Van der Leede, B. M.; Schulkes, R. A. M., Petkovich, M.; Van der Burg, B.; Van der Saag, P. T. Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptor in human breast and colon carcinoma cells. Cell Growth Differ. 1998, 9, 629-637.
26. Van Heusden, J.; Van Ginckel, R.; Bruwiere, H.; Moelans, P.; Janssen, B.; Floren, W.; Van der Leede, B. J.; Van Dun, J.; Sanz, G.; Venet, M.; Dillen, L.; Van Hove, C.; Willemsens, G.; Janicot, M.; Wouters, W. Inhibition of all-trans-retinoic acid metabolism by R116010 induces antitumor activity. Br. J. Cancer 2002, 86, 605-611.
27. Stoppie, P.; Borgers, M.; Borghgraef, P.; Dillen, L.; Goossens, J.; Sanz, G.; Szel, H.; Van Hove, C.; Van Nyen, G.; Nobels, G.; Vanden Bossche, H.; Venet, M.; Willemsens, G.; Van Wauwe, J. R115866 Inhibits all-trans-retinoic acid metabolism and exerts retinoidal effects in rodents. J. Pharmacol. Exp. Ther. 2000, 293, 304-312.
28. Vasudevan, J.; Johnson, A. T.; Huang, D.; Chandraratna, R. A. Compounds having activity as inhibitors of cytochrome P450A1. US Patent. 6,252,090, Other patents assigned to Allergan Sales, Inc., include US Patents 6,303,785 B1; 6,313,107 B1; 6,359,135 B1; 6,369,261 B1; 6,380,256 B1; 6,387,892 B1; 6,387,951 B1; 6,399,774 B1; 6,495,552 B2; and 531,599 B2.
29. (a) Kirby, A. J.; Lelain, R.; Mason, P.; Maharlouie, F.; Nicholls, P. A.; Smith, H. J.; Simons, C. Some 3-(4-aminophenyl)pyrrolidine-2,5-diones as all-trans-retinoic acid metabolising enzyme inhibitors (RAMBAs). J. Enzyme Inhib. 2002, 17, 321-327.
30. (b) Greer, V. P.; Mason, P.; Kirby, H. J.; Smith, H. J.; Nicholls, P. A.; Simons, C. Some 1,2-diphenylethane derivatives as inhibitors of retinoic acid-metabolising enzymes. J. Enzyme Inhib. 2003, 18, 431-443.
31. (c) Mason, P.; Greer, V. P.; Kirby, A. J.; Simons, C.; J.; Nicholls, P. A.; Smith, H. Some aryl substituted 2-(4-nitrophenyl)-4-oxo-4-phenylbutanoates and 3-(4-nitrophenyl)-1-phenyl-1,4-butanediols and related compounds as inhibitors of rat liver microsomal retinoic acid metabolising enzymes. J. Enzyme Inhib. 2003, 18, 511-528.
32. (a) Njar, V. C. O.; Nnane, I. P.; Brodie, A. M. H. Potent inhibition of retinoic acid metabolism enzyme(s) by novel azolyl retinoids. Bioorg. Med. Chem. Lett. 2000, 10, 1905-1908.
33. (b) Njar, V. C. O.; Patel, J.; Huynh, C. K.; Handratta, V.; Brodie, A. M. H. Synthesis of new inhibitors of all-trans-retinoic acid metabolism and their effects on proliferation of human breast cancer cells. Proceedings of the The Department of Defense Breast Cancer Research Program Meeting (Era of Hope), Orlando, FL, Sept 25-28, 2002; Abstract No. P31-17.
34. th Annual Meeting, March 27-31, 2004, Orlando, FL; Abstract No, 5604.
35. th Annual Meeting, New Orleans, LA, June 16-19, 2004; Abstract No. P1-269, pp 219.
36. 2) and its application to gas chromatographic analysis of fatty acids. Chem. Pharm. Bull 1981, 29, 1457-1477.
37. Samokyszyn, V. M.; Gall, W. E.; Zawada, G.; Freyaldenhoven, M. A.; Chen, G.; Mackenzie, P. I.; Tephyl, T. R.; Radominska-Pandya, A. 4-Hydroxyretinoic acid, a novel substrate for human liver microsomal UDP-glycuronosyltansferase(s) and recombinant UGT2B7. J. Biol. Chem. 2000, 275, 6908-6914.
38. Totleben, M. J.; Freeman, J. P.; Szmuszkovica, J. Imidazole transfer from 1,1′-carbonyldiimidazole and 1,1′-(thiocarbonyl)-diimidazole to alcohols. A new protocol for the conversion of alcohols to alkylheterocycles. J. Org. Chem. 1997, 62, 7319-7323.
39. (a) Englert, G. A 13C-NMR. Study of cis-trans isomeric vitamins A carotenoids and related compounds. Helv. Chim. Acta 1975, 58, 2367-2390.
40. (b) Dawson, M. I.; Hobbs, P. D.; Kuhlmann, K.; Fung, V. A.; Helmes, C. T.; Chao, W. Retinoic acid analogues. Synthesis and potential as cancer chemopreventive agents. J. Med. Chem. 1980, 23, 1013-1022.
41. Shealy, Y. F.; Riordan, J. M.; Frey, J. L.; Simpson-Herren, L.; Sani, B. P.; Hill, D. L. Inhibition of papilloma formation by analogs of 7,8-Dihydroretinoic acid. J. Med. Chem. 2003, 46, 1931-1939.
42. Katsuta, Y.; Ito, M.; Yoshihara, K.; Nakanishi, K.; Kikkawa, T.; Fujiwara, T. Synthesis of (+)-(4S)- and (-)-(4R)-(11Z)-4-hydroxyretinals and determination of the absolute stereochemistry of a visual pigment chromophore in the firefly squid, Watasenia scintillans. J. Org. Chem. 1994, 59, 6917-6921.
43. Taimi, M.; Breitman, T. R. N-4-Hydroxyphenylretinamide enhances retinoic acid-induced differentiation and retinoylation of proteins in the human acute promyelocytic leukemia cell line, NB4, by a mechanism that may involve inhibition of retinoic acid metabolism. Biochem. Biophys. Res. Commun. 1997, 232, 432-436.
44. Roberts, A. B.; Lamb, L. C.; Sporn, M. B. Metabolism of all-trans-retinoic acid in hamster liver microsomes. Oxidation of 4-hydroxy to 4-keto-retinoic acid. Arch. Biochem. Biophys. 1980, 199, 374-383.
45. Van Wauwe, J. P.; Coene, M.-C.; Goossens, J.; Van Nyen, G.; Cools, W.; Lauwers, W. Ketoconazole inhibits the in vitro and in vivo metabolism of all-trans-retinoic acid. J. Pharmacol. Exp. Ther. 1988, 245, 718-722.
46. Kim, S. Y.; Kim, C.; Han, I. S.; Lee, S. C.; Kim, S. H.; Lee, K., Choi, Y.; Byun, Y. Inhibition effect of new farnesol derivatives on all-trans-retinoic acid metabolism. Metabolism 2001, 50, 1356-1360.
47. Botta, M.; Corelli, F.; Gasparrini, F.; Messina, F.; Mugnaini, C. Chiral azole derivatives, 4. Enantiomers of bifonazole and related antifungal agents: Synthesis, configuration assignment, and biological evaluation, J. Org. Chem. 2000, 65, 4736-4739.
48. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proleferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63.
49. Idres, N.; Marill, J.; Flexor, M. A.; Chabot, G. G. Activation of retinoic acid receptor-dependent transcription by all-trans-retinoic acid metabolites and isomers. J. Biol. Chem. 2002, 277, 31491-31498.
50. Gavrieli, Y.; Sherman, Y.; Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of DNA fragmentation. J. Cell Biol. 1992, 119, 493-502.
51. Hsieh, T. C.; Xu, W.; Chiao, J. W. Growth regulation and cellular changes during differentiation of human prostatic cancer LNCaP cells as induced by T lymphocyte-conditioned medium. Exp. Cell Res. 1995, 218, 137-143.
52. Hall, A. K. Liarozole amplifies retinoid-induced apoptosis in human prostate cancer cells. Anti-Cancer Drugs 1996, 7, 312-320.
53. Njar, V. C. O. High-yield synthesis of novel imidazoles and triazoles from alcohols and phenols. Synthesis 2000, 14, 2019-2028.
54. Scafonas, A.; Wolfgang, C. L.; Gabriel, J. L.; Soprano, K. J.; Soprano, D. R. Differential role of homologous positively charged residues for ligand binding in retinoic acid receptor compared with retinoic acid receptor. J. Biol. Chem. 1997, 272, 11244-11249.
55. 236, plays an important role in the binding of retinoic acid by retinoic acid receptor. J. Biol. Chem. 1998, 273, 4016-4021.
56. 289 in RARγ and its homologous amino acid residue of RARα and RARβ in the binding of retinoic acid. Arch. Biochem. Biophys. 2000, 380, 339-346.
57. Wolfgang, C. L.; Zhang, Z.-p.; Gabriel, J. L.; Pieringer, R. A.; Soprano, K. J.; Soprano, D. R. Identification of sulfhydryl-modified cysteine residues in the ligand binding pocket of retinoic acid receptor β. J. Biol. Chem. 1997, 272, 746-753.
58. Zhang, Z. P.; Hutcheson, J. M.; Poynton, H. C.; Gabriel, J. L.; Soprano, K. J.; Soprano, D. R. Arginine of retinoic acid receptor β which coordinates with the carboxyl group of retinoic acid functions independent of the amino acid residues responsible for retinoic acid receptor subtype ligand specificity. Arch. Biochem. Biophys. 2003, 409, 375-384.